Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
April 26, 2019

Belite Bio to trial new therapy for macular degeneration

Biopharmaceutical firm Belite Bio has received the US Food and Drug Administration (FDA) approval to conduct a Phase I clinical trial of LBS-008 (BPN-14967) to treat dry macular degeneration and Stargardt disease.

Biopharmaceutical firm Belite Bio has received the US Food and Drug Administration (FDA) approval to conduct a Phase I clinical trial of LBS-008 (BPN-14967) to treat dry macular degeneration and Stargardt disease.

LBS-008 is an oral therapeutic designed to prevent the accumulation of toxins (A2E), which are by-products of vitamin A and cause progressive retinal cell death and permanent vision loss.

The therapy minimises and regulates the retinol-binding protein 4 (RBP4) that carries vitamin A to the eye. Belite Bio noted that LBS-008 does not directly affect the visual cycle of the eye.

“We’re encouraged by the ongoing favourable regulatory view of our technology, including a recent systematic review published by the UK National Institute for Health Research.”

LBS-008 secured orphan drug designation (ODD) in the US and EU in 2017 and 2018, respectively. It also has rare paediatric disease designation in the US for Stargardt disease.

The development of the therapy has been funded the US National Institute of Health (NIH) Blueprint Neurotherapeutics Network (Blueprint Program), which will also support the Phase I single ascending dose trial.

Belite Bio chairman Tom Lin said: “We’re encouraged by the ongoing favourable regulatory view of our technology, including a recent systematic review published by the UK National Institute for Health Research identifying the reduction of serum RBP4 as the most promising treatments for dry AMD and Stargardt disease.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

“We plan to continue to work closely with our collaborators and leverage the Blueprint Program’s resources and support to move LBS-008 to the next clinical and regulatory milestone.”

Dry macular degeneration, a primary cause of vision loss in the US, currently lacks approved therapies.

Stargardt disease is an inherited juvenile type of macular degeneration, which leads to progressive vision loss beginning in childhood. The majority of patients become visually impaired by the age of 20.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU